- Glenmark Life Sciences spikes 11% in early trade on listing day; what should investors do now?
- Exxaro Tiles IPO sees healthy demand from investors, issue subscribed 15.35 times on final day
- Exxaro Tiles IPO sees healthy demand from investors, issue subscribed 22 times on final day
- Exxaro Tiles IPO sees healthy demand from investors, issue subscribed 22.67 times on final day
- Exxaro Tiles IPO sees healthy demand from investors, issue subscribed 16.22 times on final day
- Exxaro Tiles IPO sees healthy demand from investors, issue subscribed 22.58 times on final day
- Exxaro Tiles IPO sees healthy demand from investors, issue subscribed 14.88 times on final day
- Exxaro Tiles IPO sees healthy demand from investors, issue subscribed 21.44 times on final day
- Windlas Biotech IPO oversubscribed by 22 times, QIB portion booked 24.4 times on final day
- Windlas Biotech IPO oversubscribed by 22.47 times, QIB portion booked 24.4 times on final day
- Windlas Biotech IPO oversubscribed by 13.26 times, QIB portion booked 7.4 times on final day
- Windlas Biotech IPO oversubscribed by 10.74 times, QIB portion booked 1.76 times on final day
- Windlas Biotech IPO oversubscribed by 21 times, QIB portion booked 22 times on final day
- Windlas Biotech IPO oversubscribed by 22.4 times, QIB portion booked 24.4 times on final day
- Windlas Biotech IPO oversubscribed by 12.35 times, QIB portion booked 5.87 times on final day